Cargando…

A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)

BACKGROUND: Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients, health care systems and society due to increasing incidence and poor survival rates. In recent years, advances in the treatment of metastatic NSCLC have resulted from the introduction of targeted therapies. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lange, Ansgar, Prenzler, Anne, Frank, Martin, Golpon, Heiko, Welte, Tobias, von der Schulenburg, J-Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269853/ https://www.ncbi.nlm.nih.gov/pubmed/25471553 http://dx.doi.org/10.1186/1471-2466-14-192

Ejemplares similares

Treatment‐related experiences and preferences of patients with lung cancer: a qualitative analysis
por: Aumann, Ines, et al.
Publicado: (2015)

Therapy preferences of patients with lung and colon cancer: a discrete choice experiment
por: Schmidt, Katharina, et al.
Publicado: (2017)

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
por: Prenzler, Anne, et al.
Publicado: (2011)

Regional differences in health care of patients with inflammatory bowel disease in Germany
por: Lange, Ansgar, et al.
Publicado: (2015)

Genome sequencing: a systematic review of health economic evidence
por: Frank, Martin, et al.
Publicado: (2013)

Impact of radiofrequency ablation for patients with varicose veins on the budget of the German statutory health insurance system
por: Kuhlmann, Alexander, et al.
Publicado: (2013)

Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting
por: Treskova, Marina, et al.
Publicado: (2017)

Potential Roles of Acute Phase Proteins in Cancer: Why Do Cancer Cells Produce or Take Up Exogenous Acute Phase Protein Alpha1-Antitrypsin?
por: Janciauskiene, Sabina, et al.
Publicado: (2021)

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
por: Kuhlmann, Alexander, et al.
Publicado: (2012)

Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension
por: Nickel, Nils P, et al.
Publicado: (2013)

Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
por: Gottlieb, Jens, et al.
Publicado: (2023)

Are there social gradients in the occurrence of lung cancer and in the survival of lung cancer patients? Findings from an observational study using German claims data of Lower Saxony
por: Schröder, Sebastian, et al.
Publicado: (2020)

Compression, expansion, or maybe both? Growing inequalities in lung cancer in Germany
por: Tetzlaff, Fabian, et al.
Publicado: (2020)

The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Sama, Srikar, et al.
Publicado: (2022)

Age- and gender-based comorbidity categories in general practitioner and pulmonology patients with COPD
por: Kim-Dorner, Su-Jong, et al.
Publicado: (2022)

Costs and treatment patterns of incident ADHD patients - a comparative analysis before and after the initial diagnosis -
por: Klora, Mike, et al.
Publicado: (2015)

Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC
por: Florez (DUMA), Narjust, et al.
Publicado: (2023)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
por: Lavacchi, Daniele, et al.
Publicado: (2019)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
por: Plagemann, Thomas, et al.
Publicado: (2011)

Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors
por: Wahler, Steffen, et al.
Publicado: (2022)

Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency
por: Koczulla, A-Rembert, et al.
Publicado: (2012)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany
por: Birkemeyer, Ralf, et al.
Publicado: (2020)

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients
por: Alharbi, Mohammed, et al.
Publicado: (2017)

Socioeconomic inequalities in lung cancer – a time trend analysis with German health insurance data
por: Tetzlaff, Fabian, et al.
Publicado: (2021)

Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
por: Pereira, José Rodrigues, et al.
Publicado: (2004)

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies
por: Scarpace, Sarah L
Publicado: (2015)

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
por: Melosky, Barbara
Publicado: (2017)

Endobronchial ultrasound guided fine needle aspiration versus transcervical mediastinoscopy in nodal staging of non small cell lung cancer: a prospective comparison study
por: Zhang, Ruoyu, et al.
Publicado: (2012)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Staging of non-small cell lung cancer (NSCLC)
por: Rankin, S C
Publicado: (2006)

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
por: Singh, Charu
Publicado: (2014)

SDPS-42 METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN EDEMA: A TOPOGRAPHICAL AND CLINICOPATHOLOGIC INVESTIGATION
por: Yun, Jonathan, et al.
Publicado: (2023)

Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries
por: Wahler, Steffen, et al.
Publicado: (2022)

Evolution of surface-based deformable image registration for adaptive radiotherapy of non-small cell lung cancer (NSCLC)
por: Guckenberger, Matthias, et al.
Publicado: (2009)

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
por: Zer, Alona, et al.
Publicado: (2014)

Dividend policy issues in the European pharmaceutical industry: new empirical evidence
por: Basse, Tobias, et al.
Publicado: (2022)

KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
por: Chen, Hanxiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nnlhf524hqkgevf18gagbum83u